1 1 2 3 4 14 (1. 100730;2. 100190;3. 100190; 4. 100190) : [ ] (PLGA) MCF7 [ ] MCF7 Zeta ; [ ] MCF7 75nm MCF7 85% 3 (P<0.05) [ ] MCF7 MCF7 : ; ; ; :R737.9 :A :1004-0242(2010)06-0400-05 Preparation of Breast Cancer Cell Lysates-loaded Nanoparticle and Preliminary Evaluation of Its Immunity in vitro MA Jin 1 DUAN Jin-hong 1 ZHANG Qi-jun 2 et al. (1.Institute of Basic Medicine Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100005 China; 2.Technical Institute of Physics and Chemistry Chinese Academy of Science Beijing 100190 China) Abstract: [Purpose] To prepare nanoparticle for encapsulating MCF7 breast cancer cell lysate protein (MCF7p) with poly (D L-lactide co-glycolide) copolymer (PLGA) and to evaluate its role in immunotherapy for breast cancer. [Methods] The double emulsion method was employed for preparation of nanoparticles (NP) encapsulating the MCF7 breast cancer cell lysate protein. The morphology size zeta potential and encapsulation efficiency of the NP were assayed and optimized. The NP was utilized to simulate the peripheral blood mononuclear cells (PBMC) and the anti-tumor immune reaction of NP was detected in vitro. [Results] The obtained NPs were negatively charged spherical in shape relatively uniform in size with a mean diameter of 75nm and a protein encapsulation rate of 85%.The NP-stimulated PMBC generated a significantly higher anticancer cytotoxicity in vitro with 3 times compared to the control group(p<0.05). [Conclusion] The NPs prepared are of good physicochemical properties and can encapsulate protein antigen with high efficiency. Moreover the NPs significantly enhance the immunogenicity of the MCF7 tumor lysate protein suggesting that nanotechnology may have potential applications in immunotherapy against cancer. Key words: tumor lysate protein; nanoparticles; breast cancer; immunotherapy [2] :2010-01-21; :2010-03-05 [1] : (2006CB933204 9030600490406024)China Medical Board : E-mail: ayangmd@gmail.com 400 2010 19 6 China Cancer2010Vol.19No.6
); ; 1 2 1 4 1 8 [3] ; 1.2 1.2.1 MCF7 1.2.3 NP MCF7 80% 0.25% ( NP [4] 0.01%EDTA) RPMI- (poly lactic-co-glycolic acidplga) 1640 : D-hanks (%)=( - )/ FDA 100% 1mol/L NaOH [6] cocktail( NP cocktail 100 PLGA 1) 4 2h : MCF7 4 12 000r/min 15min (%)=NP / -80 100% 1.2.2 1 (nanoparticlesnp) (W1/ [5] O/W2) 1.2.4 MCF7 NPs MCF7 ( 1.1 1.25% 188 ) 1ml 25 (pro- PLGA tease inhibitor cocktail Zeta Sigma ); 5% 1~2 (PLGA 50 50 16 000g/mol ); 188( ); ( );Bradford 30min 1.2.5 MTS BCA MCF7 NPs ( MCF7 NP NP );MTS( )( 96 ) (Promega );RPMI-1640 ( (PBMC) 4 ); (FBS : HyClone ); ( ); NP ( (T cells +NP 2010 19 6 China Cancer2010Vol.19No.6 401
); MCF7 (T cells+mcf7 ); MCF7 (MCF-NP) (T (1) cells+mcf7-np ) 72h MCF7 0.1μg/ml MCF7 (polydispersity 96 MCF7 indexpdi) 0.202<0.5 37 1 4 1 8 75nm ( 4h (1) 2)Zeta -22.7mV (3) E T( : 1 MCF7 ) MCF7 (180s ) 2 (120s ); 1 MTS 1 5 1 ( (%) ) ( 21.67% 2 1 8 27.08 1 4 20.50 ) MCF7 83.27% 1 2 10.71 ( 2) :PLGA =10mg; 1 D-hanks 3 100μl RPMI-1640 20μl MTS 37 1 5 1h A490 : (80%) (%)=1-(A490 -A490 2.2 MCF7 )/(A490 -A490 ) 100% MCF7 1.3 SPSS 13.0 t 2 2.1 (W1/O/W2) 402 2010 19 6 China Cancer2010Vol.19No.6
100000 80000 60000 40000 3 20000 0-200 -100 0 100 Zeta (mv) 3 MCF7 50 40 30 20 10 0 T cells+mcf7 T cells+np T cells+mcf7-np *:P<0.05 ;#:P<0.05T cells+mcf7 ;E T=20 1 4 MCF7 2.3 MCF7 (P<0.05) 4 2.4 PLGA MCF7 PLGA NP FDA Tcells+NP PBMC [7] MCF7 MTS NP MCF7 MCF7 (PBMC) MCF7 4 T 30% ( cells+np 30nm~200nm PBMC) MCF7 11.74%±7.98% ( PBMC MCF7 [4] 9.36%±5.92%) 10% PLGA (%) 2010 19 6 China Cancer2010Vol.19No.6 403
[5] Bilati U Allemann E Doelker E. [8] Poly (DL-lactide-co-glycolide) proteinloaded nanoparticles prepared by the Zeta double emulsion method --processing and formulation issues for enhanced entrapment efficiency [J]. J Microencapsul Zeta 30mV 2005 22(2): 205-214. [9] Zeta [6] Solbrig CM Saucier-Sawyer JK : Cody V et al. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor [1] Baxevanis CN Perez SA Papamichail M. Cancer immunotherapy [J]. cells[j]. Mol Pharm 2007 4(1): 47-57. [7] Cohen S Yoshioka T Lucarelli M ( 75nm) Crit Rev Clin Lab Sci 2009 46(4): 167- et al. Controlled delivery systems for 189. proteins based on poly (lactic/glycolic [2] Blattman JN Greenberg PD. Cancer acid) microspheres[j]. Pharm Res 1991 immunotherapy: a treatment for the 8(6): 713-720. masses [J]. Science 2004 305 (5681): [8] Dobrovolskaia MA Aggarwal P 200-205. Hall JB et al. Preclinical studies to understand nanoparticle interaction with [3] Dubsky P Hayden H Sachet M et al. Allogeneic tumor lysate can serve as the immune system and its potential effects both antigen source and protein supplementation for dendritic cell culture [J]. on nanoparticle biodistribution [J]. Mol Pharm 2008 5(4): 487-495. Cancer Immunol Immunother 2008 57 [9] Woitiski CB Neufeld RJ Ribeiro (6): 859-870. AJ et al. Colloidal carrier integrating [4] Watari F Takashi N Yokoyama A biomaterials for oral insulin delivery: influence of component formulation on et al. Material nanosizing effect on living organisms: non-specific biointeractive physicochemical and biological parameters[j]. Acta Biomater 2009 5(7): 2475- physical size effects [J]. J R Soc Inter- 2009 6( Suppl 3): S371-388. T face 2484. 404 2010 19 6 China Cancer2010Vol.19No.6